Elite in Lung Adenocarcinoma

Dr. Justin F. Gainor

Oncology | Hematology
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Lung Adenocarcinoma
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Justin Gainor is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Gainor is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Gainor is currently accepting new patients.

His clinical research consists of co-authoring 238 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Lung Adenocarcinoma.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Drug
Study Drugs: DKY709, PDR001
Study Phase: Phase 1
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Bevacizumab
Study Phase: Phase 1/Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Vopratelimab, Ipilimumab
Study Phase: Phase 2
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 10 Less Clinical Trials

238 Total Publications

ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
Journal: The oncologist
Published: April 22, 2025
Similar Doctors
Elite in Lung Adenocarcinoma
Dr. Lecia V. Sequist
Oncology | Hematology
Elite in Lung Adenocarcinoma
Dr. Lecia V. Sequist
Oncology | Hematology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (10.3 miles away)
781-487-2900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lecia Sequist is an Oncologist and a Hematologist in Waltham, Massachusetts. Dr. Sequist is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Sequist is currently accepting new patients.

Elite in Lung Adenocarcinoma
Dr. Bruce E. Johnson
Oncology
Elite in Lung Adenocarcinoma
Dr. Bruce E. Johnson
Oncology
450 Brookline Ave, Dana-farber Cancer Institute, 
Boston, MA 
 (2.7 miles away)
617-632-4790
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Johnson is an Oncologist in Boston, Massachusetts. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Johnson is currently accepting new patients.

Elite in Lung Adenocarcinoma
Dr. David J. Kwiatkowski
Oncology
Elite in Lung Adenocarcinoma
Dr. David J. Kwiatkowski
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kwiatkowski is an Oncologist in Boston, Massachusetts. Dr. Kwiatkowski has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Mesothelioma, and Non-Small Cell Lung Cancer (NSCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gainor's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile